Transthyretin Amyloidosis Treatment Market is Expected To Witness A Robust CAGR of 55.4% Over The Forecast Period 2018–2026 Analysed With Global Players Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc.

Transthyretin amyloidosis is a rare inherited and slowly progressive disease characterized by abnormal buildup of deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Two main type of transthyretin amyloidosis includes hereditary transthyretin amyloidosis and wild type transthyretin amyloidosis. Hereditary transthyretin amyloidosis is further divided into polyneuropathy, cardiomyopathy, and mixed type. Diagnosis of transthyretin amyloidosis includes approaches such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers such as N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for diagnosis of the disease. Genetic testing for transthyretin gene mutations is performed in case of familial transthyretin amyloidosis diagnosis.

Request For In-Depth Sample Copy of Exclusive Report @ https://www.coherentmarketinsights.com/insight/request-sample/687

Transthyretin Amyloidosis Treatment Market - Key Players

Key players operating in the global transthyretin amyloidosis treatment market include,

1. Alnylam Pharmaceuticals, Inc.
2. Pfizer, Inc.
3. Prothena Corporation Plc.
4. GlaxoSmithKline Plc.
5. Ionis Pharmaceuticals, Inc.
6. Eidos Therapeutics
7. SOM Innovation Biotech, S.L.

Market Dynamics

Approvals and launches of novel therapies for the treatment of transthyretin amyloidosis is expected to be a major factor driving the market growth over the forecast period. In October 2018, Eidos Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its drug candidate AG10, indicated for the treatment of ATTR. In October 2018, Ionis Pharmaceuticals, Inc. and its Akcea Therapeutics Inc., received approval for its drug TEGSEDITM (inotersen injection) in Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). In October 2018, Ionis Pharmaceuticals, Inc. and its Akcea Therapeutics Inc., received approval for its drug TEGSEDITM (inotersen injection) in Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)

Furthermore, increasing number under development drugs for the treatment of transthyretin amyloidosis are expected to gain approval in the near future. Therefore, presence of such robust pipeline is expected to boost the market growth. For instance, GlaxoSmithKline plc. a pharmaceutical company, is developing dezamizumab (2398852)† +2315698†, a combination of GSK2398852 (anti-SAP mAb) and GSK2315698 (CPHPC) for the treatment of amyloidosis. Currently, the product is under phase 2 clinical trial.

Introduction of novel therapy for the treatment of transthyretin amyloidosis is expected to significantly drive the market growth

Key players in the market are focused on approval and launch of novel therapies for treatment of transthyretin amyloidosis. This in turn is expected to propel growth of the global transthyretin amyloidosis treatment market over the forecast period. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection— a RNA interference (RNAi) therapeutic— indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

The global transthyretin amyloidosis treatment market size is expected to be valued at US$ 35.8 million in 2018 and is expected to witness a robust CAGR of 55.4% over the forecast period (2018–2026).

Detailed Segmentation:

Global Transthyretin Amyloidosis Treatment Market, by Drug Type:
• Tafamidis (Vyndaqel)
• Patisiran (ONPATTRO)
• Inotersen (TEGSEDI)
• Others

Global Transthyretin Amyloidosis Treatment Market, by Disease Type:
• Hereditary Transthyretin Amyloidosis
• Polyneuropathy
• Cardiomyopathy
• Mixed Type
• Wild Type Amyloidosis

Global Transthyretin Amyloidosis Treatment Market, by Distribution Channel:
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Transthyretin Amyloidosis Treatment Market, By Geography:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Else Place and Enquiry Before Purchase This Business Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/687

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.